ZA200308989B - Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. - Google Patents

Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. Download PDF

Info

Publication number
ZA200308989B
ZA200308989B ZA200308989A ZA200308989A ZA200308989B ZA 200308989 B ZA200308989 B ZA 200308989B ZA 200308989 A ZA200308989 A ZA 200308989A ZA 200308989 A ZA200308989 A ZA 200308989A ZA 200308989 B ZA200308989 B ZA 200308989B
Authority
ZA
South Africa
Prior art keywords
cellulose acetate
substituted
drug
optionally
polymer
Prior art date
Application number
ZA200308989A
Other languages
English (en)
Inventor
Crew Marshall David
Friesen Dwayne Thomas
Ketner Rodney James
Shanker Ravi Mysore
West James Blair
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200308989B publication Critical patent/ZA200308989B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)
  • Quinoline Compounds (AREA)
ZA200308989A 2001-06-22 2003-11-19 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. ZA200308989B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30025601P 2001-06-22 2001-06-22

Publications (1)

Publication Number Publication Date
ZA200308989B true ZA200308989B (en) 2004-11-19

Family

ID=23158332

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200308989A ZA200308989B (en) 2001-06-22 2003-11-19 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers.

Country Status (28)

Country Link
US (3) US20030054038A1 (fr)
EP (1) EP1399190B1 (fr)
JP (1) JP2004534822A (fr)
KR (1) KR20040011549A (fr)
CN (1) CN1545421A (fr)
AT (1) ATE480226T1 (fr)
BG (1) BG108488A (fr)
BR (1) BR0210530A (fr)
CA (1) CA2450762A1 (fr)
CO (1) CO5540325A2 (fr)
CR (1) CR7171A (fr)
CZ (1) CZ20033457A3 (fr)
DE (1) DE60237602D1 (fr)
EA (1) EA200301250A1 (fr)
EC (1) ECSP034913A (fr)
EE (1) EE200400033A (fr)
HU (1) HUP0400264A2 (fr)
IL (1) IL158991A0 (fr)
IS (1) IS7047A (fr)
MA (1) MA27039A1 (fr)
MX (1) MXPA03011933A (fr)
NO (1) NO20035699D0 (fr)
OA (1) OA12624A (fr)
PL (1) PL368587A1 (fr)
SK (1) SK15732003A3 (fr)
TN (1) TNSN03137A1 (fr)
WO (1) WO2003000292A1 (fr)
ZA (1) ZA200308989B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (fr) * 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002013999A1 (fr) * 2000-08-11 2002-02-21 Ishihara Sangyo Kaisha, Ltd. Solution metallique colloidale, procede de production de cette solution et materiau de revetement contenant cette solution
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
JP2004534812A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
ATE407670T1 (de) * 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20070059346A1 (en) * 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
CN100508976C (zh) * 2003-07-24 2009-07-08 史密丝克莱恩比彻姆公司 口腔溶解薄膜
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
JP2007501217A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク コレステリルエステル転送タンパク質阻害剤を制御放出し、そしてＨＭＧ−ＣｏＡレダクターゼ阻害剤を即時放出する投薬形態
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8207232B2 (en) * 2004-05-28 2012-06-26 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
WO2006064906A1 (fr) * 2004-12-17 2006-06-22 Ono Pharmaceutical Co., Ltd. Composition amorphe
US8617604B2 (en) * 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
DE102005007059A1 (de) * 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008047201A2 (fr) * 2006-10-17 2008-04-24 Pfizer Products Inc. Preparation sechee par atomisation
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008098195A2 (fr) * 2007-02-09 2008-08-14 Todd Maibach Film comprenant de la nitroglycérine
GB0703627D0 (en) * 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
GB2446953A (en) * 2007-02-24 2008-08-27 Agt Sciences Ltd Aqueous pharmaceutical formulations
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
US20120015032A1 (en) * 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
EP2240162A4 (fr) * 2007-12-06 2013-10-09 Bend Res Inc Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
KR20100093591A (ko) * 2007-12-12 2010-08-25 바스프 에스이 활성 구성성분과 중합체 반대이온의 염
US20100184870A1 (en) * 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
ES2552723T3 (es) * 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
AU2010326099B2 (en) 2009-12-03 2013-03-07 Novartis Ag Carboxyvinyl polymer-container nanoparticle suspensions
EP2600837A1 (fr) 2010-08-03 2013-06-12 G. Pohl-Boskamp GmbH & Co. KG Utilisation de trinitrate de glycéryle pour le traitement d'hématomes
PL2678000T3 (pl) 2011-02-25 2018-08-31 G. Pohl-Boskamp Gmbh & Co. Kg Stabilizowane granulaty zawierające triazotan glicerolu
CA2865917C (fr) * 2011-03-01 2020-09-29 4413261 Canada Inc. (Spencer Canada) Systeme monolithique a deux vitesses pour la liberation controlee de medicaments
AU2012295397A1 (en) * 2011-08-16 2014-02-20 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
HUE033092T2 (hu) 2012-05-31 2017-11-28 G Pohl-Boskamp Gmbh & Co Kg Arteriogenezis indukálása nitroglicerinnel mint nitrogén-oxid donorral
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
CN105228623A (zh) * 2013-03-14 2016-01-06 夏尔人类遗传性治疗公司 治疗b2-缓激肽受体介导的血管性水肿的方法
EP2878310B1 (fr) 2013-11-29 2017-01-11 G. Pohl-Boskamp GmbH & Co. KG Composition aqueuse pulvérisable comprenant du trinitrate de glycéryle
WO2015141662A1 (fr) * 2014-03-18 2015-09-24 武田薬品工業株式会社 Dispersion solide
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CN106999432A (zh) 2014-12-05 2017-08-01 阿拉贡药品公司 抗癌组合物
BR112018074763A2 (pt) * 2016-06-23 2019-03-06 Dow Global Technologies Llc éteres de celulose esterificados que compreendem grupos ftalila
BR112019003048A2 (pt) * 2016-08-23 2019-05-21 Dow Global Technologies Llc ftalato de acetato de éter de celulose
KR102634735B1 (ko) * 2016-12-21 2024-02-07 더 코카콜라 컴파니 저용해도 성분을 분배하기 위한 음료 분배기
US10347667B2 (en) * 2017-07-26 2019-07-09 International Business Machines Corporation Thin-film negative differential resistance and neuronal circuit
EP3773509B1 (fr) 2018-04-06 2023-11-01 Capsugel Belgium NV Procédé de séchage par pulvérisation pour des particules à faible rapport d'aspect comprenant du poly[(méthacrylate de méthyle)-co-(acide méthacrylique)]
WO2020027011A1 (fr) 2018-07-30 2020-02-06 中外製薬株式会社 Dispersion solide de dérivé d'hydantoïne
CA3146466A1 (fr) * 2019-08-15 2021-02-18 Warren K. Miller Ammoniac en tant qu'auxiliaire de traitement pour des dispersions solides pulverisees
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
WO2023086832A1 (fr) * 2021-11-09 2023-05-19 Board Of Regents, The University Oftexas System Procédés de préparation de formes posologiques à l'aide d'une impression 3d contenant des dispersions solides amorphes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565629A (en) * 1896-08-11 Fastener for bottles
US522520A (en) * 1894-07-03 Flower-holder for florists use
US103225A (en) * 1870-05-17 andrew myers
US2830987A (en) * 1958-04-15 Derivatives of phenthiazine
US2784185A (en) * 1953-03-27 1957-03-05 Promonta Chem Fab Phenothiazine compounds
US2901478A (en) * 1957-02-11 1959-08-25 Promonta Chem Fab Phenothiazine compounds
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4689319A (en) * 1983-01-13 1987-08-25 Colorado State University Research Foundation Oral energy rich therapy for diarrhea in mammals
JPS59193832A (ja) 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製法
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4867970A (en) 1987-05-21 1989-09-19 E. R. Squibb & Sons, Inc. Moistureless oral drug delivery formulation and method for preparing same
US4835186A (en) 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
FR2632521B1 (fr) * 1988-06-10 1990-09-14 Rhone Poulenc Sante Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0462066A1 (fr) 1990-06-15 1991-12-18 Warner-Lambert Company Gemfibrozil amorphe
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
WO1993011749A1 (fr) 1991-12-18 1993-06-24 Warner-Lambert Company Procede de preparation d'une dispersion solide
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
DE19637517A1 (de) * 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
US6306434B1 (en) * 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EP1027887B1 (fr) 1999-02-10 2008-08-13 Pfizer Products Inc. Dispositif pour la libération du principe actif contrôlée par la matrice
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027888B1 (fr) 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
DE19918434A1 (de) * 1999-04-23 2000-10-26 Basf Ag Feste Pharmazeutische Formulierungen von säurelabilen Protonenpumpenblockern
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
NZ518480A (en) 1999-10-27 2004-02-27 Cytokinetics Inc Methods and compositions utilizing quinazolinones
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1360180A1 (fr) 2001-01-19 2003-11-12 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine

Also Published As

Publication number Publication date
SK15732003A3 (sk) 2005-01-03
EA200301250A1 (ru) 2004-06-24
ECSP034913A (es) 2004-01-28
IS7047A (is) 2003-11-20
OA12624A (en) 2006-06-12
DE60237602D1 (de) 2010-10-21
US8147872B2 (en) 2012-04-03
US8173142B2 (en) 2012-05-08
NO20035699D0 (no) 2003-12-19
PL368587A1 (en) 2005-04-04
US20060204577A1 (en) 2006-09-14
MA27039A1 (fr) 2004-12-20
WO2003000292A1 (fr) 2003-01-03
EP1399190B1 (fr) 2010-09-08
TNSN03137A1 (fr) 2005-12-23
EP1399190A1 (fr) 2004-03-24
EE200400033A (et) 2004-06-15
CZ20033457A3 (cs) 2004-09-15
HUP0400264A2 (hu) 2004-08-30
MXPA03011933A (es) 2004-03-26
CO5540325A2 (es) 2005-07-29
JP2004534822A (ja) 2004-11-18
CN1545421A (zh) 2004-11-10
CA2450762A1 (fr) 2003-01-03
BR0210530A (pt) 2004-06-22
KR20040011549A (ko) 2004-02-05
ATE480226T1 (de) 2010-09-15
BG108488A (bg) 2005-01-31
US20060003011A1 (en) 2006-01-05
CR7171A (es) 2004-02-23
IL158991A0 (en) 2004-05-12
US20030054038A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
ZA200308989B (en) Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers.
CA2448864C (fr) Compositions pharmaceutiques contenant une dispersion solide d'un medicament peu soluble dans une matrice et d'un polymere ameliorant la solubilite
AU2002302903B9 (en) Pharmaceutical compositions of adsorbates of amorphous drug
OA12350A (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors.
WO2001012227A1 (fr) Composition contenant un ains et un inhibiteur de kinase du regf destinee au traitement ou a l'inhibition de polypes du colon et du cancer colorectal
WO2003000226A2 (fr) Compositions pharmaceutiques contenant des ensembles polymere et medicament
EP1404300A1 (fr) Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
ZA200410212B (en) Use of CETP inhibitors and antihypertensive agentsas well as optionally HMG CoA reductase inhibitor s
MXPA02006316A (es) Composiciones farmaceuticas que comprenden farmaco y polimeros potenciadores de la concentracion.
HRP20100111T1 (hr) Nova formulacija doze
JP2006514923A (ja) 注射可能な新規なデポ製剤
TW201427661A (zh) 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑
MXPA05003162A (es) Agentes mejoradores de absorbibilidad de droga.
KR101631644B1 (ko) 수술후 접착의 치료를 위한, 히스타민 ｈ4 길항제의 용도
US20080207644A1 (en) Therapeutic materials and methods
CN116322680A (zh) Parp抑制剂的联合用药方案
AU2002229142B2 (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
TR2022009843T2 (tr) Geli̇şti̇ri̇lmi̇ş salim modeli̇ ve dağilma mekani̇zmasina sahi̇p kati oral farmasöti̇k gemi̇floksasi̇n mesi̇lat kompozi̇syonu
AU2002302886A1 (en) Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
AU2002229142A1 (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors